Open Access

Clinical outcome and dose volume evaluation in patients who undergo brachytherapy for angiosarcoma of the scalp and face

  • Authors:
    • Tomohide Sanada
    • Hidetsugu Nakayama
    • Ryokichi Irisawa
    • Mitsuru Okubo
    • Ryoji Tsuboi
    • Koichi Tokuuye
  • View Affiliations

  • Published online on: February 6, 2017     https://doi.org/10.3892/mco.2017.1155
  • Pages: 334-340
  • Copyright: © Sanada et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The present study was conducted to retrospectively evaluate survival and local control with definitive brachytherapy in patients with cutaneous angiosarcoma of the scalp and/or face, and to determine the optimal radiation dose and irradiated volume. Between November, 2009 and January, 2015, 9 consecutive patients with histologically proven angiosarcoma of the scalp and/or face who received image‑guided brachytherapy were retrospectively evaluated. The median age of the patients was 83.4 years (range, 67.7‑91.9 years). Of the 9 patients, 8 had no lymph node metastasis and 1 patient had cervical lymph node metastasis. The patients were irradiated with a dose of 3 Gy three times per week for varying lengths of time; 4 patients received a total dose of 60 Gy, 1 received 48 Gy and the 4 remaining patients received 45 Gy. The patient who received 48 Gy also underwent additional electron therapy of 16 Gy in 8 fractions. The overall survival, progression‑free survival and local progression‑free rates at 3 years were 50.8% [95% confidence interval (CI): 15.6‑78.1%], 37.0% (95% CI: 6.8‑69.3%) and 77.8% (95% CI: 36.5‑93.9%), respectively. The local progression‑free rate in the 4 patients who received a total of ≥60 Gy was statistically significantly better compared with that in the 5 patients who received a dose of <60 Gy (P=0.027). A total of 7 patients had grade 2 radiation dermatitis, whereas the remaining 2 patients had grade 3 dermatitis. All the patients had grade 2 alopecia. Local disease control achieved by radiotherapy resulted in higher survival. Therefore, prescribing ≥60 Gy in 20 fractions for the gross tumor volume is recommended for angiosarcoma of the scalp and face.
View Figures
View References

Related Articles

Journal Cover

March-2017
Volume 6 Issue 3

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Sanada T, Nakayama H, Irisawa R, Okubo M, Tsuboi R and Tokuuye K: Clinical outcome and dose volume evaluation in patients who undergo brachytherapy for angiosarcoma of the scalp and face. Mol Clin Oncol 6: 334-340, 2017
APA
Sanada, T., Nakayama, H., Irisawa, R., Okubo, M., Tsuboi, R., & Tokuuye, K. (2017). Clinical outcome and dose volume evaluation in patients who undergo brachytherapy for angiosarcoma of the scalp and face. Molecular and Clinical Oncology, 6, 334-340. https://doi.org/10.3892/mco.2017.1155
MLA
Sanada, T., Nakayama, H., Irisawa, R., Okubo, M., Tsuboi, R., Tokuuye, K."Clinical outcome and dose volume evaluation in patients who undergo brachytherapy for angiosarcoma of the scalp and face". Molecular and Clinical Oncology 6.3 (2017): 334-340.
Chicago
Sanada, T., Nakayama, H., Irisawa, R., Okubo, M., Tsuboi, R., Tokuuye, K."Clinical outcome and dose volume evaluation in patients who undergo brachytherapy for angiosarcoma of the scalp and face". Molecular and Clinical Oncology 6, no. 3 (2017): 334-340. https://doi.org/10.3892/mco.2017.1155